Simone Cesaro, MD, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy, describes current challenges in pediatric hematopoietic stem cell transplantation (HSCT), including the late approval of new treatments. Dr Cesaro highlights the need to efficiently indicate novel drugs in a pediatric setting so that these patients can receive quality care in an expedient manner. This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.